Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have been given an average rating of “Hold” by the five brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $11.00.

NBTX has been the topic of a number of research analyst reports. Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Wall Street Zen upgraded Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Wednesday, October 8th.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. purchased a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,356 shares of the company’s stock, valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Price Performance

NBTX stock opened at $20.49 on Tuesday. The firm has a 50-day moving average price of $21.04 and a 200-day moving average price of $11.62. Nanobiotix has a 12 month low of $2.76 and a 12 month high of $30.35.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.